A Review of Randomized Controlled Trials of Hereditary Angioedema Long-Term Prophylaxis with C1 Inhibitor Replacement Therapy: Alleviation of Disease Symptoms Is Achievable

References

• Bygum A, Busse P, Caballero T, Maurer M. Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema. Front Med. 2017;4:212. doi:10.3389/fmed.2017.00212
   Web of Science ®Google Scholar
• Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. Allergy. 2022;77(7):1961–1990. doi:10.1111/all.15214
   PubMed Web of Science ®Google Scholar
• Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–274. doi:10.1016/j.amjmed.2005.09.064
   PubMed Web of Science ®Google Scholar
• Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol. 2006;154(3):542–545. doi:10.1111/j.1365-2133.2005.07048.x
   PubMed Web of Science ®Google Scholar
• Csuka D, Veszeli N, Imreh E, et al. Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2015;10:132. doi:10.1186/s13023-015-0351-5
   PubMed Web of Science ®Google Scholar
• Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999;104(6):1321–1322. doi:10.1016/S0091-6749(99)70030-8
   PubMed Web of Science ®Google Scholar
• Levi M, Cohn DM, Zeerleder S. Hereditary angioedema: linking complement regulation to the coagulation system. Res Pract Thromb Haemost. 2019;3(1):38–43. doi:10.1002/rth2.12175
   PubMed Web of Science ®Google Scholar
• Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3suppl):S51–S131. doi:10.1016/j.jaci.2004.06.047
   PubMedGoogle Scholar
• Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382(12):1136–1148. doi:10.1056/NEJMra1808012
   PubMed Web of Science ®Google Scholar
• Levy D, Craig T, Keith PK, Krishnarajah G, Beckerman R, Prusty S. Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: a systematic literature review. Allergy Asthma Clin Immunol. 2020;16:41. doi:10.1186/s13223-020-00437-x
   PubMed Web of Science ®Google Scholar
• Brickman CM, Tsokos GC, Balow JE, et al. Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol. 1986;77(5):749–757. doi:10.1016/0091-6749(86)90424-0
   PubMed Web of Science ®Google Scholar
• Ballanti E, Perricone C, Greco E, et al. Complement and autoimmunity. Immunol Res. 2013;56(2–3):477–491. doi:10.1007/s12026-013-8422-y
   PubMed Web of Science ®Google Scholar
• Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132–150. doi:10.1016/j.jaip.2020.08.046
   PubMed Web of Science ®Google Scholar
• Hack CE, Relan A, van Amersfoort ES, Cicardi M. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy. 2012;67(1):123–130. doi:10.1111/j.1398-9995.2011.02716.x
   PubMed Web of Science ®Google Scholar
• Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(1):58–64. doi:10.1016/j.tripleo.2011.02.034
   PubMed Web of Science ®Google Scholar
• Perego F, Gidaro A, Zanichelli A, et al. Life expectancy in Italian patients with hereditary angioedema due to C1-inhibitor deficiency. J Allergy Clin Immunol Pract. 2020;8(5):1772–1774. doi:10.1016/j.jaip.2020.01.007
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol. 2010;126(5):918–925. doi:10.1016/j.jaci.2010.08.012
   PubMed Web of Science ®Google Scholar
• Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131–1140. doi:10.1056/NEJMoa1613627
   PubMed Web of Science ®Google Scholar
• Späth PJ, Wuthrich B, Butler R. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema – evidence of a functionally critical level of C1-inhibitor concentration. Complement. 1984;1(3):147–159. doi:10.1159/000467830
   PubMedGoogle Scholar
• Valerieva A, Caccia S, Cicardi M. Recombinant human C1 esterase inhibitor (conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema. Expert Rev Clin Immunol. 2018;14(9):707–718. doi:10.1080/1744666X.2018.1503055
   PubMed Web of Science ®Google Scholar
• Riedl MA, Grivcheva-Panovska V, Moldovan D, et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet. 2017;390(10102):1595–1602. doi:10.1016/S0140-6736(17)31963-3
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513–522. doi:10.1056/NEJMoa0805538
   PubMed Web of Science ®Google Scholar
• Craig T, Zuraw B, Longhurst H, et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2019;7(6):1793–1802.e2. doi:10.1016/j.jaip.2019.01.054
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Cicardi M, Longhurst HJ, et al. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy. 2015;70(10):1319–1328. doi:10.1111/all.12658
   PubMed Web of Science ®Google Scholar
• Aygören-Pürsün E, Soteres DF, Nieto-Martinez SA, et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatr Allergy Immunol. 2019;30(5):553–561. doi:10.1111/pai.13060
   PubMed Web of Science ®Google Scholar
• Lumry WR, Martinez-Saguer I, Yang WH, et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. J Allergy Clin Immunol Pract. 2019;7(5):1610–1618.e4. doi:10.1016/j.jaip.2019.01.021
   PubMed Web of Science ®Google Scholar
• Ruconest (C1 esterase inhibitor [recombinant]) for intravenous use, lyophilized powder for reconstitution. package insert. Pharming Americas BV; 2020. Available from: https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf. Accessed February 3, 2023.
   Google Scholar
• Longhurst HJ. Kallikrein inhibition for hereditary angioedema. N Engl J Med. 2017;376(8):788–789. doi:10.1056/NEJMe1611929
   PubMed Web of Science ®Google Scholar
• Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020;360:1–8.
   Google Scholar
• Eurostat. Overweight and obesity - BMI statistics. Available from: https://ec.europa.eu/eurostat/statistics-explained/SEPDF/cache/12376.pdf. Accessed April 22, 2022.
   Google Scholar
• Bernstein JA, Manning ME, Li H, et al. Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2014;2(1):77–84. doi:10.1016/j.jaip.2013.09.008
   PubMed Web of Science ®Google Scholar
• CSL Behring. Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) for Subcutaneous Injection, Freeze-Dried Powder for Reconstitution. CSL Behring; 2022.
   Google Scholar
• Takeda Pharmaceuticals U.S.A., Inc. Cinryze (C1 Esterase Inhibitor [Human]) for Intravenous Use, Freeze-Dried Powder for Reconstitution. Takeda Pharmaceuticals U.S.A., Inc; 2021.
   Google Scholar